Surgery Partners (SGRY) Competitors

$14.48 +0.17 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$14.48 -0.01 (-0.03%)

As of 06:39 PM Eastern

SGRY vs. THC, HIMS, CELC, CAI, and PACS

Should you buy Surgery Partners stock or one of its competitors? MarketBeat compares Surgery Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surgery Partners include Tenet Healthcare (THC), Hims & Hers Health (HIMS), Celcuity (CELC), Caris Life Sciences (CAI), and PACS Group (PACS).

How does Surgery Partners compare to Tenet Healthcare?

Tenet Healthcare (NYSE:THC) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Tenet Healthcare has higher revenue and earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Tenet Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenet Healthcare	$21.31B	0.80	$1.41B	$19.23	10.35
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

Tenet Healthcare has a net margin of 7.94% compared to Surgery Partners' net margin of -2.28%. Tenet Healthcare's return on equity of 25.55% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenet Healthcare	7.94%	25.55%	5.15%
Surgery Partners	-2.28%	1.04%	0.41%

In the previous week, Tenet Healthcare had 1 more articles in the media than Surgery Partners. MarketBeat recorded 7 mentions for Tenet Healthcare and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Tenet Healthcare's score of 0.63 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenet Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenet Healthcare has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market.

Tenet Healthcare currently has a consensus price target of $244.16, indicating a potential upside of 22.73%. Surgery Partners has a consensus price target of $22.18, indicating a potential upside of 53.19%. Given Surgery Partners' higher possible upside, analysts plainly believe Surgery Partners is more favorable than Tenet Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenet Healthcare	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

95.4% of Tenet Healthcare shares are held by institutional investors. 0.8% of Tenet Healthcare shares are held by company insiders. Comparatively, 2.7% of Surgery Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Tenet Healthcare beats Surgery Partners on 12 of the 16 factors compared between the two stocks.

How does Surgery Partners compare to Hims & Hers Health?

Surgery Partners (NASDAQ:SGRY) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Hims & Hers Health has lower revenue, but higher earnings than Surgery Partners. Hims & Hers Health is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A
Hims & Hers Health	$2.37B	2.33	$128.37M	-$0.09	N/A

Hims & Hers Health has a net margin of -0.56% compared to Surgery Partners' net margin of -2.28%. Hims & Hers Health's return on equity of 6.10% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Hims & Hers Health	-0.56%	6.10%	1.52%

In the previous week, Hims & Hers Health had 68 more articles in the media than Surgery Partners. MarketBeat recorded 74 mentions for Hims & Hers Health and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Hims & Hers Health's score of 0.02 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	17 Very Positive mention(s)	11 Positive mention(s)	10 Neutral mention(s)	23 Negative mention(s)	5 Very Negative mention(s)	Neutral

Surgery Partners has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Surgery Partners presently has a consensus price target of $22.18, suggesting a potential upside of 53.19%. Hims & Hers Health has a consensus price target of $29.50, suggesting a potential upside of 21.73%. Given Surgery Partners' stronger consensus rating and higher possible upside, analysts clearly believe Surgery Partners is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12

63.5% of Hims & Hers Health shares are owned by institutional investors. 2.7% of Surgery Partners shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Hims & Hers Health beats Surgery Partners on 10 of the 16 factors compared between the two stocks.

How does Surgery Partners compare to Celcuity?

Surgery Partners (NASDAQ:SGRY) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Surgery Partners has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A

Surgery Partners currently has a consensus target price of $22.18, indicating a potential upside of 53.19%. Celcuity has a consensus target price of $134.50, indicating a potential downside of 0.16%. Given Surgery Partners' higher possible upside, analysts clearly believe Surgery Partners is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Celcuity had 5 more articles in the media than Surgery Partners. MarketBeat recorded 11 mentions for Celcuity and 6 mentions for Surgery Partners. Celcuity's average media sentiment score of 1.28 beat Surgery Partners' score of 1.13 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Surgery Partners has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

63.3% of Celcuity shares are held by institutional investors. 2.7% of Surgery Partners shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Celcuity has a net margin of 0.00% compared to Surgery Partners' net margin of -2.28%. Surgery Partners' return on equity of 1.04% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Celcuity	N/A	-203.17%	-52.68%

Summary

Surgery Partners beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does Surgery Partners compare to Caris Life Sciences?

Surgery Partners (NASDAQ:SGRY) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Caris Life Sciences has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A
Caris Life Sciences	$812.03M	5.31	-$68.09M	-$7.61	N/A

Surgery Partners currently has a consensus target price of $22.18, indicating a potential upside of 53.19%. Caris Life Sciences has a consensus target price of $27.56, indicating a potential upside of 80.69%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Caris Life Sciences had 17 more articles in the media than Surgery Partners. MarketBeat recorded 23 mentions for Caris Life Sciences and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Caris Life Sciences' score of 0.16 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Caris Life Sciences has a net margin of 3.75% compared to Surgery Partners' net margin of -2.28%. Caris Life Sciences' return on equity of 98.28% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Caris Life Sciences	3.75%	98.28%	48.87%

Summary

Caris Life Sciences beats Surgery Partners on 8 of the 13 factors compared between the two stocks.

How does Surgery Partners compare to PACS Group?

Surgery Partners (NASDAQ:SGRY) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

PACS Group has a net margin of 4.49% compared to Surgery Partners' net margin of -2.28%. PACS Group's return on equity of 26.47% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
PACS Group	4.49%	26.47%	4.36%

PACS Group has higher revenue and earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A
PACS Group	$5.29B	1.19	$191.54M	$1.56	25.46

Surgery Partners has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, PACS Group has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

In the previous week, PACS Group had 7 more articles in the media than Surgery Partners. MarketBeat recorded 13 mentions for PACS Group and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat PACS Group's score of 1.06 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Surgery Partners currently has a consensus target price of $22.18, indicating a potential upside of 53.19%. PACS Group has a consensus target price of $45.60, indicating a potential upside of 14.80%. Given Surgery Partners' higher probable upside, equities analysts plainly believe Surgery Partners is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

PACS Group beats Surgery Partners on 11 of the 15 factors compared between the two stocks.

Get Surgery Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGRY vs. The Competition

Export

Metric	Surgery Partners	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87B	$8.35B	$6.34B	$12.38B
Dividend Yield	N/A	3.03%	2.80%	5.35%
P/E Ratio	-24.13	21.76	20.90	25.61
Price / Sales	0.57	16.95	549.93	78.79
Price / Cash	8.38	81.29	43.26	56.33
Price / Book	0.61	5.65	9.93	6.96
Net Income	-$77.90M	$183.43M	$3.55B	$333.52M
7 Day Performance	1.19%	0.14%	-0.33%	0.45%
1 Month Performance	10.53%	5.21%	1.34%	4.06%
1 Year Performance	-36.41%	4.75%	41.10%	36.24%

Surgery Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGRY Surgery Partners	4.0742 of 5 stars	$14.48 +1.2%	$22.18 +53.2%	-37.6%	$1.87B	$3.31B	N/A	16,000	Positive News High Trading Volume
THC Tenet Healthcare	4.6184 of 5 stars	$185.24 +1.1%	$242.89 +31.1%	+24.0%	$16.06B	$21.31B	9.63	99,000	Analyst Downgrade
HIMS Hims & Hers Health	4.2252 of 5 stars	$27.25 -0.6%	$32.53 +19.4%	-62.3%	$6.25B	$2.35B	53.43	2,442	Trending News Earnings Report Analyst Forecast Options Volume
CELC Celcuity	1.7657 of 5 stars	$144.98 +15.4%	$134.50 -7.2%	+1,050.4%	$6.07B	N/A	N/A	40	News Coverage Positive News High Trading Volume
CAI Caris Life Sciences	4.3482 of 5 stars	$18.69 +1.2%	$28.86 +54.4%	N/A	$5.22B	$812.03M	N/A	1,846	Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGRY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surgery Partners (SGRY) Competitors

SGRY vs. THC, HIMS, CELC, CAI, and PACS

How does Surgery Partners compare to Tenet Healthcare?

Summary

How does Surgery Partners compare to Hims & Hers Health?

Summary

How does Surgery Partners compare to Celcuity?

Summary

How does Surgery Partners compare to Caris Life Sciences?

Summary

How does Surgery Partners compare to PACS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGRY vs. The Competition

Surgery Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surgery Partners (SGRY) Competitors

SGRY vs. THC, HIMS, CELC, CAI, and PACS

How does Surgery Partners compare to Tenet Healthcare?

Which has stronger valuation & earnings, THC or SGRY?

Is THC or SGRY more profitable?

Does the media prefer THC or SGRY?

Which has more risk and volatility, THC or SGRY?

Do analysts prefer THC or SGRY?

Do institutionals & insiders believe in THC or SGRY?

Summary

How does Surgery Partners compare to Hims & Hers Health?

Which has preferable earnings and valuation, SGRY or HIMS?

Is SGRY or HIMS more profitable?

Does the media favor SGRY or HIMS?

Which has more volatility and risk, SGRY or HIMS?

Do analysts recommend SGRY or HIMS?

Do insiders and institutionals have more ownership in SGRY or HIMS?

Summary

How does Surgery Partners compare to Celcuity?

Which has better valuation & earnings, SGRY or CELC?

Do analysts prefer SGRY or CELC?

Does the media prefer SGRY or CELC?

Which has more risk and volatility, SGRY or CELC?

Do insiders and institutionals have more ownership in SGRY or CELC?

Is SGRY or CELC more profitable?

Summary

How does Surgery Partners compare to Caris Life Sciences?

Which has better valuation & earnings, SGRY or CAI?

Do analysts prefer SGRY or CAI?

Does the media prefer SGRY or CAI?

Is SGRY or CAI more profitable?

Summary

How does Surgery Partners compare to PACS Group?

Is SGRY or PACS more profitable?

Which has preferable valuation and earnings, SGRY or PACS?

Which has more volatility and risk, SGRY or PACS?

Does the media favor SGRY or PACS?

Do analysts prefer SGRY or PACS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGRY vs. The Competition

Surgery Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools